| Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial DJ Kuter, JB Bussel, RM Lyons, V Pullarkat, TB Gernsheimer, FM Senecal, ... The Lancet 371 (9610), 395-403, 2008 | 1083 | 2008 |
| Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin RS Go, AA Adjei Journal of Clinical Oncology 17 (1), 409-409, 1999 | 896 | 1999 |
| Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin … TM Green, KH Young, C Visco, ZY Xu-Monette, A Orazi, RS Go, O Nielsen, ... American Society of Clinical Oncology (ASCO), 2012 | 805 | 2012 |
| MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression … S Hu, ZY Xu-Monette, A Tzankov, T Green, L Wu, A Balasubramanyam, ... Blood, The Journal of the American Society of Hematology 121 (20), 4021-4031, 2013 | 803 | 2013 |
| Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large … C Visco, Y Li, ZY Xu-Monette, RN Miranda, TM Green, A Tzankov, W Wen, ... Leukemia 26 (9), 2103-2113, 2012 | 401 | 2012 |
| Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP … ZY Xu-Monette, L Wu, C Visco, YC Tai, A Tzankov, W Liu, ... Blood, The Journal of the American Society of Hematology 120 (19), 3986-3996, 2012 | 392 | 2012 |
| Representation of minorities and women in oncology clinical trials: review of the past 14 years N Duma, J Vera Aguilera, J Paludo, CL Haddox, M Gonzalez Velez, ... Journal of oncology practice 14 (1), e1-e10, 2018 | 320 | 2018 |
| Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial AL Himelstein, JC Foster, JL Khatcheressian, JD Roberts, DK Seisler, ... Jama 317 (1), 48-58, 2017 | 314 | 2017 |
| Non‐H odgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the N ational C ancer D ata B ase from 1998 to 2011 M Al‐Hamadani, TM Habermann, JR Cerhan, WR Macon, MJ Maurer, ... American journal of hematology 90 (9), 790-795, 2015 | 299 | 2015 |
| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ... Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017 | 295 | 2017 |
| CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL … S Hu, ZY Xu-Monette, A Balasubramanyam, GC Manyam, C Visco, ... Blood, The Journal of the American Society of Hematology 121 (14), 2715-2724, 2013 | 279 | 2013 |
| Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis‐like T‐cell lymphoma: a systematic … RS Go, SM Wester Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 271 | 2004 |
| Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era G Goyal, ML Heaney, M Collin, F Cohen-Aubart, A Vaglio, BH Durham, ... Blood, The Journal of the American Society of Hematology 135 (22), 1929-1945, 2020 | 248 | 2020 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... Blood cancer journal 8 (6), 59, 2018 | 231 | 2018 |
| How I treat autoimmune hemolytic anemia RS Go, JL Winters, NE Kay Blood, The Journal of the American Society of Hematology 129 (22), 2971-2979, 2017 | 203 | 2017 |
| Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International … C Visco, A Tzankov, ZY Xu-Monette, RN Miranda, YC Tai, Y Li, W Liu, ... Haematologica 98 (2), 255, 2013 | 195 | 2013 |
| Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database DJ Rajyaguru, AJ Borgert, AL Smith, RM Thomes, PD Conway, ... Journal of Clinical Oncology 36 (6), 600-608, 2018 | 189 | 2018 |
| Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines TK Poonacha, RS Go Journal of clinical oncology 29 (2), 186-191, 2011 | 181 | 2011 |
| Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials JN George, SD Mathias, RS Go, M Guo, DH Henry, R Lyons, RL Redner, ... British journal of haematology 144 (3), 409-415, 2009 | 175 | 2009 |
| Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and … JD Gundrum, MA Mathiason, DB Moore, RS Go Journal of clinical oncology 27 (31), 5227-5232, 2009 | 169 | 2009 |
